ECSP14013285A - Variantes del factor 21 del crecimiento de fibroblastos - Google Patents

Variantes del factor 21 del crecimiento de fibroblastos

Info

Publication number
ECSP14013285A
ECSP14013285A ECSP14013285A ECSP14013285A EC SP14013285 A ECSP14013285 A EC SP14013285A EC SP14013285 A ECSP14013285 A EC SP14013285A EC SP14013285 A ECSP14013285 A EC SP14013285A
Authority
EC
Ecuador
Prior art keywords
variants
factor
fibroblasts
growth
variations
Prior art date
Application number
Other languages
English (en)
Inventor
Radmila Micanovic
Ryan James Darling
Craig Duane Dickinson
David Albert Driver
Malgorzata Donata Gonciarz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46964112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013285(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP14013285A publication Critical patent/ECSP14013285A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a variantes estables y/o farmacológicamente potentes del factor 21 de crecimiento del fibroblasto humano (FGF21), composiciones farmacéuticas que comprenden variantes del FGF21, y métodos para tratar diabetes tipo 2, obesidad, dislipidemia, o síndrome metabólico, o cualquier combinación de los mismos, usando tales variantes.
ECSP14013285 2011-10-04 2014-04-04 Variantes del factor 21 del crecimiento de fibroblastos ECSP14013285A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161542906P 2011-10-04 2011-10-04

Publications (1)

Publication Number Publication Date
ECSP14013285A true ECSP14013285A (es) 2014-05-31

Family

ID=46964112

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013285 ECSP14013285A (es) 2011-10-04 2014-04-04 Variantes del factor 21 del crecimiento de fibroblastos

Country Status (27)

Country Link
US (2) US8541369B2 (es)
EP (1) EP2763689B1 (es)
JP (1) JP6060167B2 (es)
KR (1) KR20140059271A (es)
CN (1) CN103906530B (es)
AP (1) AP2014007532A0 (es)
AR (1) AR087973A1 (es)
AU (1) AU2012318956A1 (es)
BR (1) BR112014007532A2 (es)
CA (1) CA2843520A1 (es)
CL (1) CL2014000801A1 (es)
CO (1) CO6910165A2 (es)
CR (1) CR20140142A (es)
DO (1) DOP2014000050A (es)
EA (1) EA201490521A1 (es)
EC (1) ECSP14013285A (es)
ES (1) ES2548214T3 (es)
IL (1) IL230754A0 (es)
IN (1) IN2014CN00782A (es)
MA (1) MA35458B1 (es)
MX (1) MX2014004159A (es)
PE (1) PE20142044A1 (es)
SG (1) SG11201401792UA (es)
TN (1) TN2014000096A1 (es)
TW (1) TWI461435B (es)
WO (1) WO2013052311A1 (es)
ZA (1) ZA201400882B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
KR102077721B1 (ko) 2011-07-01 2020-02-14 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법
WO2013173158A1 (en) * 2012-05-15 2013-11-21 Eli Lilly And Company Therapeutic uses of fibroblast growth factor 21 proteins
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
AU2013274639A1 (en) 2012-06-11 2014-11-06 Eli Lilly And Company Fibroblast growth factor 21 variants
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
CN108888757A (zh) 2012-12-27 2018-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
RU2701434C2 (ru) 2014-01-24 2019-09-26 Нгм Биофармасьютикалс, Инк. Связывающие белки и способы их применения
JP6712230B2 (ja) * 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP3209681A4 (en) 2014-10-23 2018-10-31 NGM Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
KR20240024362A (ko) 2014-10-24 2024-02-23 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
US10744185B2 (en) 2015-11-09 2020-08-18 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of pruritus
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
WO2017220706A1 (en) * 2016-06-22 2017-12-28 Novo Nordisk A/S Pharmaceutical compositions of fgf21 derivatives and uses thereof
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN106432509B (zh) * 2016-09-13 2019-05-21 河南师范大学 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用
CN106220724B (zh) * 2016-09-13 2019-10-11 河南师范大学 人成纤维细胞生长因子21重组蛋白及其制备方法和应用
CN106397607A (zh) * 2016-09-13 2017-02-15 河南师范大学 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用
EP3596130A4 (en) 2017-03-14 2020-12-30 Sunshine Lake Pharma Co., Ltd. DOUBLE TARGET FUSION PROTEINS WITH FC PORTION OF AN IMMUNE LOBULIN
SG11202001379WA (en) 2017-09-08 2020-03-30 Bristol Myers Squibb Co Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
CN116098989A (zh) 2018-02-08 2023-05-12 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
CN114903978A (zh) * 2018-07-03 2022-08-16 百时美施贵宝公司 Fgf-21配制品
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN111944055B (zh) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
TW202140074A (zh) 2020-01-08 2021-11-01 美商必治妥美雅史谷比公司 Fgf-21結合物調配物
CN115322794A (zh) 2020-01-11 2022-11-11 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
KR102495299B1 (ko) * 2020-11-03 2023-02-06 토드제약 주식회사 Fgf21의 열탄력성을 이용한 fgf21 생산 방법
WO2022115597A1 (en) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
JP4477013B2 (ja) * 2003-12-10 2010-06-09 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
PT1789442E (pt) 2004-09-02 2009-11-11 Lilly Co Eli Muteínas do factor de crescimento de fibroblasto 21
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
DK3248610T3 (da) 2009-05-05 2024-01-15 Amgen Inc Fgf21-mutanter og anvendelser deraf
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof

Also Published As

Publication number Publication date
SG11201401792UA (en) 2014-08-28
ES2548214T3 (es) 2015-10-14
US8883726B2 (en) 2014-11-11
EP2763689A1 (en) 2014-08-13
US8541369B2 (en) 2013-09-24
PE20142044A1 (es) 2014-12-06
JP2014530220A (ja) 2014-11-17
AP2014007532A0 (en) 2014-03-31
US20130085098A1 (en) 2013-04-04
BR112014007532A2 (pt) 2017-04-04
MX2014004159A (es) 2015-02-12
WO2013052311A1 (en) 2013-04-11
DOP2014000050A (es) 2014-04-15
CA2843520A1 (en) 2013-04-11
AU2012318956A1 (en) 2014-02-06
EA201490521A1 (ru) 2014-07-30
TW201326198A (zh) 2013-07-01
AR087973A1 (es) 2014-04-30
CL2014000801A1 (es) 2014-09-12
CO6910165A2 (es) 2014-03-31
EP2763689B1 (en) 2015-08-12
CR20140142A (es) 2014-05-02
IN2014CN00782A (es) 2015-04-03
IL230754A0 (en) 2014-03-31
KR20140059271A (ko) 2014-05-15
TN2014000096A1 (en) 2015-07-01
JP6060167B2 (ja) 2017-01-11
ZA201400882B (en) 2016-02-24
TWI461435B (zh) 2014-11-21
MA35458B1 (fr) 2014-09-01
CN103906530B (zh) 2016-01-20
CN103906530A (zh) 2014-07-02
US20130324460A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
ECSP14013285A (es) Variantes del factor 21 del crecimiento de fibroblastos
ECSP14030742A (es) Proteínas del factor 21 de crecimiento del fibroblasto
MX2014015258A (es) Variantes del factor 21 de crecimiento de fibroblasto.
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
CL2013002414A1 (es) Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension.
CR20150149A (es) Proteínas de fusión para el tratamiento de un síndrome metabólico
CR20140141A (es) Proteinas de funcion dual para el tratamiento de desordenes metabolicos
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
UY34859A (es) Análogos peptídicos de la exendina 4.
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
CR20110255A (es) Nuevos compuestos 578
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
UY35668A (es) Derivados de azabencimidazol como agonistas de ampk y composiciones farmacéuticas que los contienen
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
BR112013025610A2 (pt) uso de um metapneumovírus aviário vivo, e, composição farmacêutica
EA201590782A1 (ru) Оксирановые амины
CL2011003050A1 (es) Compuestos derivados de 17beta-alquil-17alfa-oxi-estratrienos sustituidos; compuestos intermediarios derivados de oxitrienos; composicion farmaceutica; utiles en el tratamiento de trastornos dependientes del estrogeno.
CL2011002626A1 (es) Compuestos derivados de piperazina, como antagonistas del receptor p2y12; composicion farmaceutica que los contienen; y su uso en el tratamiento de trastornos vasculares oclusivos.